informCLL™: A Disease Registry for Patients With Chronic Lymphocytic Leukemia

InformCLL is a multicenter, prospective, observational registry of CLL patients designed to
characterize and describe treatment patterns for those initiating treatment with approved
oral kinase inhibitors, BCL-2 inhibitors and other approved anti-CLL therapies/regimens. The
registry will provide information on regimens used to treat first-line and later lines of
CLL/SLL as well as the sequencing of treatment regimens. The registry will also evaluate the
association of these treatment patterns with patient characteristics, healthcare resource
utilization, and functional outcomes including patient-reported HRQoL. These data will
provide information to physicians that may help guide clinical practice and appropriate use
of therapies, and will also provide information on HRQoL and healthcare resource utilization
that will be of interest to healthcare decision makers.

Inclusion Criteria:

- Age of at least 18 years

- Clinical diagnosis of CLL/SLL that meets published diagnostic criteria (Hallek 2008)

- Initiating treatment within ±45 days of enrollment with novel therapies including oral
kinase inhibitors (e.g., inhibitors of BTK [e.g., ibrutinib],inhibitors of BCL-2
pathway [ e.g venetoclax] or PI3K [e.g., idelalisib]), or with other anti-CLL
therapies/regimens approved at the time of patient enrollment

- Availability of documentation of previous CLL/SLL treatment and duration of response
in the patient's medical records

- Willing and able to provide informed consent

- Willing and able to complete PRO instrument

- Willing and able to provide information on patient survey questionnaire

- Willing and able to provide a blood sample at time of enrollment

Exclusion Criteria:

- Diagnosis of B-cell malignancies other than CLL/SLL

- Estimated life expectancy <6 months

- Currently receiving treatment in an interventional clinical trial with a non-approved,
investigational agent for CLL/SLL at study entry (note: patients who enroll in an
interventional clinical trial after enrollment may remain in the registry)